PROPER-GERD: A Prospective Crossover Study to Evaluate Probe Placement Optimization for Reflux Testing in Women and Lower-BMI Patients

ConditionGERD
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-90
SponsorUniversity of Chicago

About this trial

This is a prospective, within-subject controlled study involving simultaneous dual placement of wireless Bravo pH probes in each participant. Patients will receive pH testing when symptomatic for gastroesophageal reflux disease (GERD) to confirm diagnosis as part of standard of care. Each test is 96 hours with a symptom diary, GERD-HRQL, and RSI collected, which is also standard of care for patients presenting with GERD symptoms.

Eligibility criteria

Qualifiers

Adults aged 18-90

Typical GERD symptoms (heartburn, regurgitation, chest discomfort)

No prior foregut surgery

Ability to undergo endoscopy with sedation and consent

Disqualifiers

Known motility disorders (e.g., achalasia)

Barrett's esophagus >3 cm

Pregnancy

Chronic opioid use

Trial design

Treatments tested in this trial

  • Bravo pH monitoring sessions

Treatment groups

80 Participants
are divided into 1 treatment group

Sponsors and collaborators